Neuroleptic malignant syndrome with risperidone

Pharmacotherapy

Volumn 17, Issue 3, 1997, Pages 617-621

  Gleason, Patrick P ^a,b   Conigliaro, Rosemarie L ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DANTROLENE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN 2 ANTAGONIST;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROLEPTIC MALIGNANT SYNDROME; ORAL DRUG ADMINISTRATION; PSYCHOSIS;

AGED; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; NEUROLEPTIC MALIGNANT SYNDROME; RISPERIDONE; SEROTONIN ANTAGONISTS;

EID: 0030965302     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
2. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986;143:1587-90.
3. Guze BH, Baxter LR Jr. Neuroleptic malignant syndrome. N Engl J Med 1985;313:163-6.
4. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
5. Keck PE, McElroy SL, Pope HG. Epidemiology of neuroleptic syndrome. Psychiatr Ann 1991;21:148-51.
6. Ayd FJ. Fatal hyperpyrexia during chlorpromazine treatment. J Clin Exp Psychopathol Q Rev Psychiatry Neurol 1956;17:189-92.
7. Thornberg SA, Ereshefsky L. Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 1993;13:510-14.
8. Leyson JE, Gommeren W, Eens A, de Chaffey de Courcelles D, Stoff JC, Janssen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-70.
9. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-18.
10. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
11. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol [abstr]. Clin Neuropharmacol 1992;15(suppl 1, part A):90A-1.
12. Mann SC, Caroff SN, Lazarus A. Pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 1991;21:175-80.
13. Rampertaap MP. Neuroleptic malignant syndrome. South Med J 1986;79:331-6.
14. Keck PE, Pope HG, McElroy SL. Declining frequency of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 1991;148:880-2.
15. Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989;46:914-18.
16. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull 1988;24:25-9.
17. Rosebush PI, Stewart TD, Gelenburg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant therapy in 15 patients. J Clin Psychiatry 1989;50:295-8.
18. Sporer KA. The serotonin syndrome. Drug Safety 1995;13:94-104.
19. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
20. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995;15(suppl 1):4S-10.
21. Ganelin L, Lichtenberg PS, Marcus EL, Munter RG. Suspected neuroleptic malignant syndrome in a patient receiving clozapine. Ann Pharmacother 1996;30:248-50.
22. Raitasuo V, Vataja R, Elomaa E. Risperidone-induced neuroleptic malignant syndrome in a young patient. Lancet 1994;344:1705.
23. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome. Lancet 1994;344:1228-9.
24. Murray S, Haller E. Risperidone and NMS? Psychiatric Services 1995;46:951.
25. Singer S, Richards C, Boland RJ. Two cases of risperidone-induced neuroleptic malignant syndrome. Am J Psychiatry 1995;152:1233-4.
26. Kern JL, Cernek PK. Delayed risperidone-induced neuroleptic malignant syndrome. Ann Pharmacother 1996;30:300.
27. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227-33.
28. Carloff SN, Mann SC, Lazarus A, Sullivan K, MacFadden W. Neuroleptic malignant syndrome: diagnostic issues. Pyschiatr Ann 1991;21:130-47.
29. Sewell DD, Jeste DV. Distinguishing neuroleptic malignant syndrome (NMS) from NMS-like acute medical illness: a study of 34 cases. J Neuropsychiatry 1992;4:265-9.
30. Gurrera RJ, Chang SS, Romero JA. A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992;53:56-62.
31. Marinac JS, Foxworth JW, Willsie SK. Dextromethorphan polymorphic hepatic oxidation (CYP2D6) in healthy black American adult subjects. Ther Drug Monit 1995;17:120-4.
32. Evans WE, Relling MV, Rahman A, et al. Genetic basis for lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 1993;91:2150-4.
33. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.